Follow us for updates
© 2022
Read the Story →

Moderna's New COVID Vaccine Targets Both Omicron, Original COVID

Its "lead candidate" for booster shots.
by Agence France Presse
Just now
Photo/s: Reuters

WASHINGTON -- U.S. biotech company Moderna on Wednesday said it got positive results for a new vaccine that targets both the original COVID-19 strain and omicron, and sees the shot as its "lead candidate" for a booster this fall.

The so-called "bivalent" vaccine was tested in a trial of 814 adults and shown to produce 1.75 times more omicron-specific neutralizing antibodies, which have the power to prevent infection, compared to Moderna's original Spikevax vaccine.

READ: Is a Fourth COVID Vaccine Dose Effective vs Omicron?

All of the participants previously received three doses of Spikevax, and then slightly more than half went on to get a fourth dose of the bivalent shot while the rest got another dose of Spikevax. Antibody levels were tested one month later.

The group that got the new shot also received slightly superior protection to the ancestral strain of COVID-19 compared to Spikevax -- though original COVID-19 has long since disappeared from circulation.

Continue reading below ↓

"We are thrilled,"  said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.

"We want to be as ready as early as August for shipping," he added to investors in a call.


Philippines Detects Omicron Sub-Variant From South Africa

With New Omicron Sub-Variant in PH, Filipinos Urged to Get Booster Shots

Omicron Symptoms Last 3 Days Shorter for Boosted Persons: Study

The results were broadly welcomed by experts, who agreed Moderna's vaccine is now the front runner as a booster, though some gave a note of caution. 

"We won't know about clinical outcomes until later this year," tweeted Eric Topol, a physician and scientist at Scripps Research Translational Institute. The study concerns only antibody levels, which are thought to serve as a useful proxy for how a vaccine will perform, but can't make precise predictions.

Continue reading below ↓
Recommended Videos

Breakthrough infections have risen since omicron became dominant in late 2021, with vaccine makers hoping to restore efficacy to previous levels, even as first generation vaccines continue to protect well against severe disease and death.

Omicron sub-variants challenge

Moderna officials did concede during the investor call that antibody levels would be lower against omicron's sub-variants that are now in circulation, but said it believed it was still a superior booster than repeating Spikevax. 

The BA.2.12.12 variant is currently dominant, followed by BA.2, with BA.4 and BA.5 rising, according to Centers for Disease Control and Prevention (CDC) data. Each successive omicron sub-variant appears to have a transmission advantage over those that came before it.

Moderna also doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.

The problem of an ever-evolving virus poses a challenge for health authorities.  A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.

Continue reading below ↓

"Society is moving toward a new normal that may well include annual COVID-19 vaccination alongside seasonal influenza vaccination," top FDA officials wrote in a letter to the Journal of the American Medical Association in May.

President Joe Biden's government has said it has enough funds to deliver additional boosters for those at highest risk this fall -- including the elderly and those with immune compromised conditions. 

But whether these vaccines will be made widely available to the general public for free could depend on whether Congress authorizes $22.5 billion (about P1.2 trillion) in funding the White House is seeking.

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
With the reopening of several local destinations, this app has never been more timely.
Agriculture solon is agrarian reform chief.
Wondering what's the status of your National ID?
None were paid out of her personal funds, SOCE showed.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.